The strength of our research team here in the Department of Ophthalmology is highlighted, in part, by their funding.
Astra Dinculescu PhD
Assistant Professor
Grants:
-
Jan 2024
ACTIVE
A modified arrestin1 to enhance glycolysis in photoreceptors as a therapeutic approach to slowing retinal degenerationNATL INST OF HLTH NEI · Co-Investigator
-
Sep 2023
ACTIVE
CLARIN 1 RETINAL FUNCTION AND THERAPEUTIC IMPLICATIONS FOR USH3NATL INST OF HLTH NEI · Principal Investigator
-
Sep 2022
–
Aug 2024
Generation and Characterization of Novel Large Animal Models of Usher Syndrome Type 3NATL INST OF HLTH NEI · Principal Investigator
-
Jun 2021
–
Jun 2024
Generation and Characterization of Swine Models of Usher Syndrome Type 3FOU FOR FIGHTING BLINDNESS · Principal Investigator
-
Jul 2017
–
Aug 2019
The role of basal C1QTNF5-S163R mutant deposits in drusen formation: implications for AMDBRIGHTFOCUS FOU · Principal Investigator
-
Sep 2016
–
Aug 2022
CLARIN 1 RETINAL FUNCTION AND THERAPEUTIC IMPLICATIONS FOR USH3NATL INST OF HLTH NEI · Principal Investigator
William W Hauswirth PhD
Eminent Scholar
Grants:
-
Feb 2020
–
Aug 2021
Preclinical Validation for ADVM-062 in Knock-Out and C198R Knock-In Missense Mouse Models of BCMADVERUM BIOTECHNOLOGIES INC · Principal Investigator
-
Sep 2019
–
Mar 2021
Disease mechanisms of cone opsin mutants and treatment strategiesNATL INST OF HLTH NEI · Co-Investigator
-
Mar 2019
–
Mar 2022
Mito-Targeted AAV to Treat Leber Hereditary Optic Neuropathy Caused by ND4 MutationsUNIV OF MIAMI · Principal Investigator
-
Jan 2019
–
Dec 2019
Dual Vectors for OtoferlinDECIBEL THERAPEUTICS · Principal Investigator
-
Jun 2018
–
Jun 2019
Gene Therapy for RHO adRPIVERIC BIO · Faculty
-
Apr 2018
–
Jan 2022
Translational Gene Therapy for CNGB1 Retinitis PigmentosaMICHIGAN STATE UNIV · Principal Investigator
-
Oct 2017
–
Mar 2019
Toxicology Study of BS01 in Rd1 miceAPPLIED GENETICS TECH CORP · Project Manager
-
Sep 2016
–
Aug 2021
Translational Research for Retinal Degenerative TherapiesUNIV OF PENNSYLVANIA · Principal Investigator
-
Aug 2016
–
Jul 2022
Testing Gene Therapy in Models of Geographic AtrophyNATL INST OF HLTH NEI · Project Manager
-
Jul 2016
–
Oct 2017
XLRP Mouse Toxicology StudyAPPLIED GENETICS TECH CORP · Faculty
-
Jan 2016
–
Feb 2018
AAV-Mediated Therapy for Best Vitelliform Macular DystrophyUNIV OF PENNSYLVANIA · Principal Investigator
-
Oct 2015
–
Oct 2016
DSR Match Support – Gene Therapy for ABCA4 StargarUF DIV OF SPONSORED RES MATCHING FUNDS · Principal Investigator
-
Sep 2015
–
Sep 2018
blue cone monochromancyAPPLIED GENETICS TECH CORP · Principal Investigator
-
Sep 2015
–
Aug 2016
Translational Research for Retinal Degenerative TherapiesUNIV OF PENNSYLVANIA · Principal Investigator
-
May 2015
–
Mar 2020
Gene Therapy for ABCA4 Stargardt's DiseaseAPPLIED GENETICS TECH CORP · Principal Investigator
-
Jan 2015
–
Jun 2018
Gene Therapy for Blue Cone MonochromacyBCM Families Foundation · Principal Investigator
-
Jun 2013
–
Nov 2019
rAAV-CNGB3 Gene Therapy for Achromatopsia: Translational Research StudiesNATL INST OF HLTH NEI · Principal Investigator
-
Feb 2013
–
Jan 2018
Population Coding in the RetinaCORNELL UNIV · Principal Investigator
-
Jan 2013
–
Dec 2021
Vitreal delivery of novel AAV vectors for blue cone monochromacy gene therapyUF FOUNDATION · Principal Investigator
-
Nov 2012
–
Dec 2016
XIAP gene therapy for the treatment of retinal degeneration: Safety and toxicity studies for translation into the clinicOTTAWA HOSP RESEARCH INST · Principal Investigator
-
Oct 2012
–
Sep 2016
Gene therapy using novel cone-targeted adeno-associated vital vectors in the CNGA3 sheep model of achromatopsiaUS ISRAEL BINATIONAL SCI FOU · Principal Investigator
-
Aug 2012
–
Jul 2018
Gene Therapy for CEP290 LCA and RPE DystrophiesFOU FOR FIGHTING BLINDNESS · Principal Investigator
-
Mar 2012
–
Feb 2018
Translational Gene Therapy for Rhodopsin Autosomal Dominant Retinitis Pigmentosa (Module 1)UNIV OF PENNSYLVANIA · Principal Investigator
-
Oct 2011
–
Jun 2016
Gene Therapy for LCA1FOU FOR FIGHTING BLINDNESS · Principal Investigator
-
Aug 2011
–
Jul 2016
Vision Research CoreNATL INST OF HLTH NEI · Principal Investigator
-
Jul 2011
–
Jun 2016
Module 1: Cone Targeted Gene TherapyFOU FOR FIGHTING BLINDNESS · Principal Investigator
-
Jan 2011
–
Jan 2021
Purified Recombinant Adeno Associated VirusMULTIPLE SPONSORS · Principal Investigator
-
Jan 2004
–
May 2017
03091205MACULAR VISION RESEARCH FOU · Principal Investigator
Cristhian J Ildefonso PhD
Assistant Professor
Grants:
-
Jul 2019
–
Jul 2022
Gene Therapy for Bestrophinopathies – Silent and Replace BESTIVERIC BIO · Principal Investigator
-
Jul 2017
–
Sep 2019
Local and Systemic Inflammation in a Mouse Model of RPE-oxidative DamageBRIGHTFOCUS FOU · Principal Investigator
-
Aug 2016
–
Jul 2022
Testing Gene Therapy in Models of Geographic AtrophyNATL INST OF HLTH NEI · Faculty
Qiuhong Li PhD
Associate Professor
Grants:
-
Feb 2024
ACTIVE
Fee for Service MUSCMEDICAL UNIV OF SOUTH CAROLINA · Principal Investigator
-
Sep 2023
ACTIVE
Pro/renin receptor-mediated signaling in pathogenesis of diabetic retinopathyNATL INST OF HLTH NEI · Principal Investigator
-
Aug 2023
ACTIVE
Engineering next generation probiotics for delivery of therapeuticsMEDOSOME BIOTEC · Principal Investigator
-
Dec 2022
ACTIVE
Genetically modified bacteria: Lactobacillus expression vectors producing ACE2 (LP-ACE2) and Ang-1-7 (LP-Ang-1-7) with codon usage optimized for high level expression in different species of Lactobacillus.UNIV OF ALABAMA BIRMINGHAM · Principal Investigator
-
Dec 2021
–
Nov 2022
Role of Ang(17)-secreting Lactobacillus paracasei (LP) in regulating Hypertension: Piloting Dosing StrategiesWAKE FOREST UNIV · Principal Investigator
-
Sep 2019
–
Aug 2021
Optimization of food-grade recombinant probiotics for oral delivery of ACE2/Ang-(1-7)MEDOSOME BIOTEC · Co-Investigator
-
Jun 2019
–
May 2021
Fee for Service Contract with University of Alabama (UAB)UNIV OF ALABAMA BIRMINGHAM · Principal Investigator
-
May 2018
–
Apr 2023
ACE2 Modulates the Bone Marrow- Gut Axis in Diabetic RetinopathyUNIV OF ALABAMA BIRMINGHAM · Principal Investigator
-
Aug 2016
–
Dec 2021
ACE2, Brain, Gut Dysbiosis in Pulmonary HypertensionNATL INST OF HLTH NHLBI · Co-Investigator
-
Sep 2015
–
Aug 2020
Oral therapy for diabetic retinopathy using ACE2/Ang1-7 bioencapsulated in plant cellsNATL INST OF HLTH NEI · Principal Investigator
-
Jul 2015
–
Jun 2017
Ang-(1-7)/Mas Signaling in Aging Eye- Protective Mechanisms and Therapeutic PotentialBRIGHTFOCUS FOU · Principal Investigator
-
Jan 2015
–
Dec 2017
Oral delivery of bioencapsulated ACE2 and Ang1-7 for therapy of diabetic retinopathyAMER DIABETES ASSOCIATION · Principal Investigator
-
Jan 2012
–
Dec 2016
Ocular Renin Angotensin System in Pathogenesis of Diabetic RetinopathyNATL INST OF HLTH NEI · Principal Investigator
Mark B Sherwood MD
Emeritus Professor
Grants:
-
Jun 2017
–
May 2019
OR-DRPD-ROF2017: Novel Glaucoma Drainage DevicesUF DSR OPPORTUNITY FUND · Co-Investigator
-
Oct 2015
–
Jun 2019
Glaucoma Therapy by Contact Lenses-Human TrialsUF DSR OPPORTUNITY FUND · Principal Investigator
-
Feb 2015
–
Aug 2019
192024-092 The Efficacy and Safety of Bimatoprost SR in Patients with Open-angle Glaucoma or Ocular HypertensionALLERGAN plc · Principal Investigator
-
Aug 2006
–
Sep 2022
UFF Daniels ProfessorshipUF FOUNDATION · Principal Investigator
W. Clay Smith PhD
Professor
Grants:
-
Aug 2024
ACTIVE
Biological assay of sterilant bioactivity in tissue cultureMICHELSON FOUND ANIMALS FOUNDATION · Principal Investigator
-
Jan 2024
ACTIVE
A modified arrestin1 to enhance glycolysis in photoreceptors as a therapeutic approach to slowing retinal degenerationNATL INST OF HLTH NEI · Principal Investigator
-
Nov 2023
–
Aug 2024
Michelson Task #5 Biological assay of sterilant bioactivity in tissue cultureMICHELSON FOUND ANIMALS FOUNDATION · Principal Investigator
-
Sep 2022
ACTIVE
Research Training in Vision ScienceNATL INST OF HLTH NEI · Principal Investigator
-
Apr 2022
–
Mar 2023
Biological assay of sterilant bioactivity in tissue cultureMICHELSON FOUND ANIMALS FOUNDATION · Principal Investigator
-
Jan 2022
–
Dec 2023
SBT-100 Regulation of Cytokine Signaling and Autoimmunity*SINGH BIOTECHNOLOGY · Co-Project Director/Principal Investigator
-
Apr 2021
–
Dec 2023
Mitigation of Equine Recurrent Uveitis through topical suppressor of Cytokine Signaling-1 mimetic peptideGRAYSON JOCKEY CLUB RES FOU · Co-Project Director/Principal Investigator
-
Nov 2020
–
Jun 2021
Task Order #3 – Biological assay of sterilant bioactivity in tissue cultureMICHELSON FOUND ANIMALS FOUNDATION · Principal Investigator
-
Sep 2020
–
Sep 2021
Core Equipment for Assessment of Ocular Disease in Animal ModelsNATL INST OF HLTH OD · Principal Investigator
-
Jun 2020
–
Nov 2020
Task Order #2 – Biological assay of sterilant bioactivity in tissue cultureMICHELSON FOUND ANIMALS FOUNDATION · Principal Investigator
-
Sep 2019
–
Mar 2021
Disease mechanisms of cone opsin mutants and treatment strategiesNATL INST OF HLTH NEI · Co-Investigator
-
Jul 2019
–
Feb 2020
Task Order #1 – Sterilant Bioassay for Michelson Found Animals FoundationMICHELSON FOUND ANIMALS FOUNDATION · Principal Investigator
-
Jun 2019
–
Nov 2022
Enhancing Metabolism in Photoreceptors with a Modified Arrestin to Treat Retinal DegenerationFOU FOR FIGHTING BLINDNESS · Principal Investigator
-
Mar 2016
–
Feb 2022
Research Training in vision scienceNATL INST OF HLTH NEI · Principal Investigator
-
Aug 2011
–
Jul 2016
Vision Research CoreNATL INST OF HLTH NEI · Project Manager
Sonal S Tuli MD
Professor And Chair
Grants:
-
Sep 2023
ACTIVE
Parasitic Ulcer Treatment TrialUNIV OF CALIFORNIA SAN FRANCISCO · Principal Investigator
-
Jun 2023
ACTIVE
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects with Fuchs Endothelial Corneal DystrophyKOWA RESEARCH INSTITUTE · Principal Investigator
-
Apr 2023
ACTIVE
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects with Fuchs Endothelial Corneal DystrophyKOWA RESEARCH INSTITUTE · Principal Investigator
-
Mar 2023
ACTIVE
Efficacy, Safety and Pharmacokinetics of 3 Doses of REC 0/0559 Eye Drops for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult PatientsRECORDATI RARE DISEASES · Principal Investigator
-
Apr 2021
–
Dec 2023
Mitigation of Equine Recurrent Uveitis through topical suppressor of Cytokine Signaling-1 mimetic peptideGRAYSON JOCKEY CLUB RES FOU · Co-Project Director/Principal Investigator
-
Dec 2020
–
Apr 2024
A Double-Masked, Randomised, Placebo-Controlled, Parallel Group, 12-week, Phase 2 study to investigate the safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Patients with Fuchs Endothelial Corneal DystrophyPPD INVESTIGATOR SERVICES LLC · Principal Investigator
-
Aug 2017
–
Jun 2021
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster OphthalmicusNEW YORK UNIVERSITY SCHOOL OF MEDICINE · Principal Investigator
-
May 2016
–
Mar 2021
An Observational, Multicenter Study of the Prevalence of Cerebrotendinous Xanthomatosis (CTX) in Patient Populations Diagnosed with Early-Onset Idiopathic Bilateral Cataracts Protocol Number 018CTXX15001CTI CLINICAL TRIAL SERVICES · Principal Investigator
-
Dec 2014
–
Dec 2017
Clinical Evaluation of the RPS-OH to detect Herpes Simplex VirusRAPID PATHOGEN SCREENING · Principal Investigator
-
Sep 2014
–
Aug 2016
Regulation of Stromal Wound Healing by Growth FactorsNATL INST OF HLTH NEI · Project Manager
-
Feb 2011
–
Feb 2020
Stanley Glaucoma FundUF FOUNDATION · Project Manager
-
Aug 2007
–
Dec 2020
Lion's Eye Foundation AwardNORTH FL LIONS EYE FOU · Principal Investigator
-
Jul 2007
–
Oct 2020
Retina Disease Research & Education- Equipment PurchasesUF FOUNDATION · Principal Investigator
-
Jul 2007
–
Dec 2020
Unrestricted Research GrantRESEARCH TO PREVENT BLINDNESS · Principal Investigator
-
May 2007
–
Jun 2022
Overstreet Retinal Eye Disease ResearchUF FOUNDATION · Principal Investigator